التفاصيل البيبلوغرافية
| العنوان: |
Treatment of generalized granuloma annulare with tildrakizumab. |
| المؤلفون: |
Awad, Andrew1 (AUTHOR) andrew.awad@hotmail.com, Nirenberg, Alexander2 (AUTHOR), Sinclair, Rodney1,3,4 (AUTHOR) |
| المصدر: |
Australasian Journal of Dermatology. Aug2022, Vol. 63 Issue 3, pe285-e288. 4p. 3 Color Photographs. |
| مصطلحات موضوعية: |
*GRANULOMA, *DRUG eruptions |
| مستخلص: |
Successful treatment has been described with the TNF- inhibitors adalimumab and infliximab6 as well as the Janus kinase inhibitor tofacitinib.5 Unsuccessful treatment has been reported with tildrakizumab and secukinumab.7,8 The effectiveness of tildrakizumab in our cases implicates IL23 and the TH17 axis in the pathogenesis of GA in at least our patient and underlines the likely heterogeneity in the immune mechanisms involved in the pathogenesis of GA. Granuloma annulare skin profile shows activation of T-helper cell type 1, T-helper cell type 2, and Janus kinase pathways. Keywords: granuloma annulare; granulomatous; necrobiotic; tildrakizumab EN granuloma annulare granulomatous necrobiotic tildrakizumab e285 e288 4 08/17/22 20220801 NES 220801 INTRODUCTION Granuloma annulare (GA) is a non-infectious granulomatous and necrobiotic skin disease with a relative predilection for females.1 It classically presents with one or more localized annular erythematous papules. [Extracted from the article] |
| قاعدة البيانات: |
Academic Search Index |
